Company profile
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic
- CEO
- —
- Headquarters
- Watertown, MA, United States
- Employees
- 27
- IPO date
- May 1, 2020
- Sector
- Healthcare
- Industry
- Biotechnology